Myeloma cells release soluble interleukin-6Rα in relation to disease progression by two distinct mechanisms: Alternative splicing and proteolytic cleavage

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2693-2697

  Thabard, Wilfrid ^a   Barillé, Sophie ^a   Collette, Madeleine ^a   Harousseau, Jean Luc ^b   Rapp, Marie Josée ^b   Bataille, Régis ^a   Amiot, Martine ^a,b  

^a Inst Natl de la Recherche   (France)

^b INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXAMIC ACID; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; METALLOPROTEINASE INHIBITOR;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL IMMORTALIZATION; CYTOKINE RELEASE; DISEASE ACTIVITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; TUMOR GROWTH;

ALTERNATIVE SPLICING; ENDOPEPTIDASES; HUMANS; MULTIPLE MYELOMA; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER;

EID: 0032719042     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., and Iwato, K. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (Lond.), 332: 83-85, 1988.
2. Klein, B., Zhang, X., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M., and Bataille, R. Paracrine rather than autocrine regulation of myeloma cell growth and differenciation by interleukin-6. Blood, 73: 517, 1989.
3. Kishimoto, T., Akira, S., Narazaki, M., and Taga, T. Interleukin-6 family of cytokines and gp130. Blood, 86: 1243-1254, 1995.
4. Peters, M., Jacobs, S., Ehlers, M., Vollmer, P., Müllberg, J., Wolf, E., Brem, G., Meyer, K., and Rose-John, S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice toward IL-6 and prolongation of the plasma half-life of IL-6. J. Exp. Med., 183: 1399-1406, 1996.
5. Schirmacher, P., Peters, M., Ciliberto, G., Blessing, M., Lotz, J., Büschenfelde, M. Z., and Rose-John, S. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am. J. Pathol., 153: 639-648, 1998.
6. Tamura, T., Udagawa, N., Takahashi, N., Miyaura, C., Tanaka, S., Yamada, Y., Koishihara, Y., Ohsugi, Y., Kumaki, K., Taga, T., Kishimoto, T., and Suda, T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl. Acad. Sci. USA, 90: 11924-11928, 1993.
7. Gaillard, J., Bataille, R., Brailly, H., Zuber, C., Yasukawa, K., Attal, M., Maruo, N., Taga, T., Kishimoto, T., and Klein, B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur. J. Immunol., 23: 820-824, 1993.
8. Stasi, R., Brunetti, M., Parma, A., Giulio, C., Terzoli, E., and Pagano, A. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma. Cancer (Phila.), 82: 1860-1866, 1998.
9. Gaillard, J., Liautard, J., Klein, B., and Brochier, J. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines. Eur. J. Immunol., 27: 3332-3340, 1997.
10. Diamant, M., Hansen, M., Rieneck, K., Svenson, M., Yasukawa, K., and Bendtzen, K. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors. Leukemia Res., 20: 291-301, 1996.
11. Müllberg, J., Durie, F., Otten-Evans, C., Alderson, M., Rose-John, S., Cosman, D., Black, R., and Mohler, K. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol., 155: 5198-5205, 1995.
12. Hargreaves, P., Wang, F., Antcliff, J., Murphy, G., Lawry, J., Graham, R., Russell, G., and Croucher, P. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br. J. Haematol., 101: 694-702, 1998.
13. Horiuchi, S., Koyanagi, Y., Zhou, Y., Miyamoto, H., Tanaka, Y., Waki, M., Matsumoto, A., Yamamoto, M., and Yamamoto, N. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol., 24: 1945-1948, 1994.
14. Lust, J., Donovan, K., Kline, M., Greipp, P., Kyle, R., and Maihle, N. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine, 4: 96-100, 1992.
15. Ancuta, P., Fahmi, H., Pons, J., Blay, K. L., and Chaby, R. Involvement of the membrane form of tumor necrosis factor-α in lipopolysaccharide-induced priming of mouse peritoneal macrophages for enhanced nitric oxide response to lipopolysaccharide. Immunology., 92: 259-266, 1997.
16. Pellat-Deceunynck, C., Bataille, R., Robillard, N., Harousseau, J., Rapp, M., Juge-Morineau, N., Wijdenes, J., and Amiot, M. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells, Blood, 84: 2597-2603, 1994.
17. Durie, B., and Salmon, S. Multiple myeloma, macroglobulinaemia and monoclonal gammopathies. In: A. V. Hoffbrand, M. C. Brain, and J. Hish (eds.), Recent Advances in Haematology, pp. 243-261. Edinburgh Churchill Livingstone, 1977.
18. Müllberg, J., Schooltink, H., Stoyan, T., Heinrich, P., and Rose-John, S. Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem. Biophys. Res. Commun., 189: 794-800, 1992.
19. Müllberg, J., Schooltink, H., Stoyan, T., Günther, M., and Graeve, L. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol., 23: 473-480, 1993.
20. Hata, H., Xiao, H., Petrucci, M., Woodliff, J., Chang, R., and Epstein, J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood, 81: 3357-3364, 1993.
21. Barillé, S., Thabard, W., Robillard, N., Pineau, D., Harousseau, J-L., Bataille, R., and Amiot, M. CD130 rather than CD126 expression is associated with disease activity in multiple myeloma. Br. J. Haematol., in press, 1999.
22. Gallea-Robache, S., Morand, V., Millet, S., Bruneau, J., Bhatnagar, N., Chouaib, S., and Roman-Roman, S. A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine, 9: 340-346, 1997.
23. Black, R., Rauch, C. Kozlosky, C., Peschon, J., Slack, J., Wolfson, M., Castner, B., Stocking, K., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K., Gerhart, M., Davis, R., Fitzner, J., Johnson, R., Paxton, R., March, C., and Cerretti, D. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature (Lond.), 385: 729-733, 1997.
24. Moss, M., Jin, S., Milla, M., Burkhart, W., Carter, H., Chen, W., Clay, W., Didsbury, J., Hassler, D., Hoffman, C., Kost, T., Lambert, M., Leesnitzer, M., Cauley, P., Geehan, G., Mitchell, J., Moyers, M., Pahel, G., Rocque, W., Overton, L., Schoenen, F., Seaton, T., Su, J., Warner, J., Willard, D., and Becherer, J. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature (Lond.), 385: 733-736, 1997.
25. Rosendhal, M., Ko, S., Long, D., Brewer, M., Rosenzweig, B., Hedl, E., Anderson, L., Pyle, S., Moreland, J., Meyers, M., Kohno, T., Lyons, D., and Lichenstein, H. Identification and characterization of a pro-tumor necrosis factor-α-processing enzyme from the ADAM family of zinc metalloprotease. J. Biol. Chem., 272: 24588-24593, 1997.
26. McKie, N., Dallas, D., Edwards, T., Apperley, J., and Graham, R. Cloning of a novel membrane-linked metalloproteinase from human myeloma cells. Biochem. J., 318: 459-462, 1996.
27. Cichy, J., Rose-John, S., Potempa, J., Pryjma, J., and Travis, J. Oncostatin M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells. J. Immunol., 159: 5648-5653, 1997.
28. Jones, S., Novick, D., Horiuchi, S., Yamamoto, N., Szalai, A., and Fuller, G. C-reactive proteins: a physiological activator of interleukin-6 receptor shedding. J. Exp. Med., 189: 599-604, 1999.
29. Barillé, S., Akhoundi, C, Collette, M., Mellerin, M.-P., Rapp, M.-J., Harousseau, J.-L., Bataille, R., and Amiot, M. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood, 90: 1649-1655, 1997.
30. Brown, P., and Giavazzi, R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann. Oncol., 6: 967, 1995.
31. Beattie, G., and Smyth, J. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin. Cancer Res., 8: 1899-1902, 1998.
32. Parsons, S., Watson, S., and Steele, R. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur. J. Surg. Oncol., 526-531, 1997.
33. Barille, S., Collette, M., Bataille, R., and Amiot, M. Myeloma cells up-regulate IL-6 secretion in osteoblatic cells through cell-to-cell contact but down-regulate osteocalcin. Blood, 90: 1649-1655, 1997.